10/16
08:31 am
indp
Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.